A Navy Yard biotech designed a first-of-its-kind therapy for rare cancer. Now, it waits for patients.

Press/Media

Period	Oct 8 2024

Media coverage

Title	A Navy Yard biotech designed a first-of-its-kind therapy for rare cancer. Now, it waits for patients.
Media name/outlet	Philadelphia Inquirer
Country/Territory	United States
Date	10/8/24
URL	https://www.inquirer.com/health/philadelphia-biotech-adaptimmune-cancer-tecelra-synovial-sarcoma-20241008.html
Persons	Margaret von Mehren